Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro

Biopharmaceutics and Drug Disposition

Volumn 34, Issue 5, 2013, Pages 278-287

  Yu, Lushan ^a   Shi, Da ^a   Ma, Liping ^a   Zhou, Quan ^b   Zeng, Su ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

CYP2C8; genetic polymorphisms; ibuprofen enantiomers; paclitaxel; repaglinde

Indexed keywords

CYTOCHROME B5; CYTOCHROME P450 2C8; CYTOCHROME P450 REDUCTASE; IBUPROFEN; PACLITAXEL; REPAGLINIDE;

ALLELE; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; STEREOCHEMISTRY;

CYP2C8; GENETIC POLYMORPHISMS; IBUPROFEN ENANTIOMERS; PACLITAXEL; REPAGLINDE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYL HYDROCARBON HYDROXYLASES; BACULOVIRIDAE; CARBAMATES; CYCLOOXYGENASE INHIBITORS; CYTOCHROMES B5; GENETIC VECTORS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYDROXYLATION; HYPOGLYCEMIC AGENTS; IBUPROFEN; LIVER; PACLITAXEL; PIPERIDINES; POLYMORPHISM, GENETIC;

EID: 84879846126     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1842     Document Type: Article

References (30)

1. Kawakami H, Ohtsuki S, Kamiie J, Suzuki T, Abe T, Terasaki T,. Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. J Pharm Sci 2011; 100: 341-352.
2. Rowbotham SE, Boddy AV, Redfern CP, Veal GJ, Daly AK,. Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug Metab Dispos 2010; 38: 1261-1266.
3. Gao Y, Liu D, Wang H, Zhu J, Chen C,. Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions. Xenobiotica 2010; 40: 767-775.
4. Luckow VA, Summers MD,. Trends in the development of baculovirus expression vectors. Nat Biotechnol 1988; 6: 47-55.
5. Demain AL, Vaishnav P,. Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv 2009; 27: 297-306.
6. Totah RA, Rettie AE,. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005; 77: 341-352.
7. Wattanachai N, Polasek TM, Heath TM, et al,. In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. Eur J Clin Pharmacol 2011; 67: 815-824.
8. Marsh S, Somlo G, Li X, et al,. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 2007; 7: 362-365.
9. Säll C, Houston JB, Galetin A,. A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. Drug Metab Dispos 2012; 40: 1279-1289.
10. Tomalik-Scharte D, Fuhr U, Hellmich M, et al,. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Dispos 2011; 39: 927-932.
11. Niemi M, Backman JT, Kajosaari LI, et al,. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005; 77: 468-478.
12. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ,. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 2003; 74: 380-387.
13. Hao H, Wang G, Sun J,. Enantioselective pharmacokinetics of ibuprofen and involved mechanisms. Drug Metab Rev 2005; 37: 215-234.
14. Chang SY, Li W, Traeger SC, et al,. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro. Drug Metab Dispos 2008; 36: 2513-2522.
15. Lõpez-Rodríguez R, Novalbos J, Gallego-Sandín S, et al,. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacol Res 2008; 58: 77-84.
16. Chen YK, Chen SQ, Li X, Zeng S,. Quantitative regioselectivity of glucuronidation of quercetin by recombinant UDP-glucuronosyltransferases 1A9 and 1A3 using enzymatic kinetic parameters. Xenobiotica 2005; 35: 943-954.
17. Gonzalez FJ, Kimura S, Tamura S, Gelboin HV,. Expression of mammalian cytochrome P450 using baculovirus. Methods Enzymol 1991; 206: 93-99.
18. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M,. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol 2008; 48: 311-321.
19. Dai D, Zeldin DC, Blaisdell JA, et al,. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11: 597-607.
20. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF,. Structure of human microsomal cytochrome P450 2C8. J Biol Chem 2004; 279: 9497-9503.
21. Jiang H, Zhong F, Sun L, Feng W, Huang ZX, Tan X,. Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8. Amino Acids 2011; 40: 1195-1204.
22. Jiang HL, Sun L, Huang ZX, Tan XS,. Structural and functional insights into CYP2C8.3: a genetic polymorph of cytochrome P450 2C8. Sci China Chem 2010; 53: 2200-2207.
23. Kaspera R, Naraharisetti SB, Evangelista EA, Marciante KD, Psaty BM, Totah RA,. Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem Pharmacol 2011; 82: 681-691.
24. Hamman MA, Thompson GA, Hall SD,. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 1997; 54: 33-41.
25. Green H, Soderkvist P, Rosenberg P, et al,. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol 2009; 104: 130-137.
26. Karazniewicz-Lada M, Luczak M, Glowka F,. Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes. Xenobiotica 2009; 39: 476-485.
27. Rodríguez-Antona C, Niemi M, Backman JT, et al,. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J 2008; 8: 268-277.
28. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, Johnson EF,. Determinants of cytochrome P450 2C8 substrate binding. J Biol Chem 2008; 283: 17227-17237.
29. Kerdpin O, Elliot DJ, Boye SL, Birkett DJ, Yoovathaworn K, John O,. Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. Biochemistry 2004; 43: 7834-7842.
30. Zhang H, Myshkin E, Waskell L,. Role of cytochrome b5 in catalysis by cytochrome P450 2B4. Biochem Biophys Res Commun 2005; 338: 499-506.